Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 291 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer May 7, 2021 Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... March 6, 2020 £82,000 of Donations Pour in for Mom with Incurable Cancer to... April 10, 2019 EMA Recommends Extension of Indications for Pirtobrutinib April 24, 2025 Load more HOT NEWS Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December EMA Recommends Extension of Indications for Pirtobrutinib
